Clinical Trials Logo

Cancer of the Neck clinical trials

View clinical trials related to Cancer of the Neck.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT00970502 Recruiting - Clinical trials for Cancer of the Larynx

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Start date: February 2007
Phase: Phase 1/Phase 2
Study type: Interventional

There is no optimal treatment for patients with recurrent head and neck cancer after previous radiation. Chemotherapy alone is not curative and patients survive an average of only 6 to 10 months. Surgery is not always possible and often cannot remove every cancerous cell. On the other hand, reirradiation with chemotherapy cures approximately 25 to 30% of patients but has significant toxicity with as many as 15 to 20% suffering from life-threatening or fatal complications. Therefore, less toxic and more effective reirradiation regimens are urgently needed. There are extensive data from animal studies and preliminary human studies showing that blocking epidermal growth factor receptor (EGFR) and COX-2 enhances radiation effect and is more effective than either treatment alone. Erlotinib is a FDA approved oral inhibitor of EGFR and celecoxib is a FDA approved COX-2 inhibitor. Both have been well studied in humans and appear to have less severe toxicity than conventional chemotherapeutic agents.